JP2021533747A5 - - Google Patents

Info

Publication number
JP2021533747A5
JP2021533747A5 JP2021506661A JP2021506661A JP2021533747A5 JP 2021533747 A5 JP2021533747 A5 JP 2021533747A5 JP 2021506661 A JP2021506661 A JP 2021506661A JP 2021506661 A JP2021506661 A JP 2021506661A JP 2021533747 A5 JP2021533747 A5 JP 2021533747A5
Authority
JP
Japan
Prior art keywords
cells
transgene sequence
receptor
determining
copy number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506661A
Other languages
English (en)
Japanese (ja)
Other versions
JP7538109B2 (ja
JP2021533747A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046048 external-priority patent/WO2020033916A1/en
Publication of JP2021533747A publication Critical patent/JP2021533747A/ja
Publication of JP2021533747A5 publication Critical patent/JP2021533747A5/ja
Application granted granted Critical
Publication of JP7538109B2 publication Critical patent/JP7538109B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506661A 2018-08-09 2019-08-09 組み込まれた核酸を評価するための方法 Active JP7538109B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716972P 2018-08-09 2018-08-09
US62/716,972 2018-08-09
PCT/US2019/046048 WO2020033916A1 (en) 2018-08-09 2019-08-09 Methods for assessing integrated nucleic acids

Publications (3)

Publication Number Publication Date
JP2021533747A JP2021533747A (ja) 2021-12-09
JP2021533747A5 true JP2021533747A5 (https=) 2022-08-18
JP7538109B2 JP7538109B2 (ja) 2024-08-21

Family

ID=67997674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506661A Active JP7538109B2 (ja) 2018-08-09 2019-08-09 組み込まれた核酸を評価するための方法

Country Status (13)

Country Link
US (1) US20210230671A1 (https=)
EP (1) EP3833759A1 (https=)
JP (1) JP7538109B2 (https=)
KR (1) KR102933503B1 (https=)
CN (1) CN112805378A (https=)
AU (1) AU2019316647A1 (https=)
BR (1) BR112021002245A2 (https=)
CA (1) CA3108698A1 (https=)
EA (1) EA202190469A1 (https=)
IL (1) IL280528A (https=)
MX (1) MX2021001519A (https=)
SG (1) SG11202101130VA (https=)
WO (1) WO2020033916A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
IL296319A (en) * 2020-03-09 2022-11-01 Janssen Biotech Inc Compositions and Methods for Quantifying Recombinant Vector Nucleic Acid Incorporation
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド B細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
WO2021216993A1 (en) * 2020-04-24 2021-10-28 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
EP4139451A1 (en) * 2020-04-24 2023-03-01 Sage Science, Inc. Systems, devices, and methods for electrophoretic extracting and enriching extrachromosomal dna
CN112280896A (zh) * 2020-09-30 2021-01-29 浙江大学 一种基于微滴式数字pcr技术的乙型肝炎病毒t216c突变检测方法
JP2023545126A (ja) * 2020-10-12 2023-10-26 武田薬品工業株式会社 Car-t細胞の細胞動態及び体内分布の決定
WO2023077029A2 (en) * 2021-10-27 2023-05-04 Mission Bio, Inc. Single cell viral integration site detection
CN117343927B (zh) * 2023-12-06 2024-03-12 上海药明巨诺生物医药研发有限公司 一种工程化细胞的核酸提取方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US5801115A (en) 1995-09-05 1998-09-01 Kataleuna Gmbh Catalyst composition and methods for using and preparing same
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6123655A (en) 1996-04-24 2000-09-26 Fell; Claude Cell separation system with variable size chamber for the processing of biological fluids
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
HK1041454B (en) 1998-12-24 2004-12-31 生物安全股份有限公司 Blood separation system particularly for concentrating hematopoietic stem cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
ES2345837T3 (es) 2005-03-23 2010-10-04 Biosafe S.A. Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa.
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011021629A1 (ja) * 2009-08-21 2011-02-24 旭硝子株式会社 形質転換体およびその製造方法、ならびに乳酸の製造方法
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP5954315B2 (ja) * 2011-02-21 2016-07-20 旭硝子株式会社 変異体および該変異体の培養方法
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US9599590B2 (en) 2012-10-12 2017-03-21 Sage Science, Inc. Side-eluting molecular fractionator
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗fcrh5抗體
JP6515502B2 (ja) * 2013-11-22 2019-05-22 Agc株式会社 形質転換体の製造方法、形質転換体、および単座組込み用ベクターキット
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
US10131901B2 (en) 2014-10-15 2018-11-20 Sage Science, Inc. Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation
ES2987570T3 (es) 2014-11-05 2024-11-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
BR112017011932A8 (pt) 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
ES3063691T3 (en) * 2015-09-22 2026-04-20 Univ Wuerzburg J Maximilians A method for high level and stable gene transfer in lymphocytes
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso

Similar Documents

Publication Publication Date Title
JP2021533747A5 (https=)
JP2022531222A5 (https=)
AU2018207281B2 (en) Modulating expression of polypeptides via new gene switch expression systems
JP2024138280A5 (https=)
Dotti et al. Fifteen years of gene therapy based on chimeric antigen receptors:“are we nearly there yet?”
JP7538109B2 (ja) 組み込まれた核酸を評価するための方法
JP2021510540A (ja) 修飾細胞の増幅およびその応用
AU2020418199A1 (en) Modified immune effector cell and preparation method therefor
WO2017193059A1 (en) Systems and methods for targeting cancer cells
JP2022512913A5 (https=)
CN110257338B (zh) 嵌合细胞因子受体
WO2019183389A1 (en) Chimeric transmembrane proteins and uses thereof
CN110511912B (zh) 免疫细胞的功能调节
CN108277205B (zh) 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
CN108218993B (zh) 一种以robo1为靶点的双特异性抗体及其制备和应用
JP2022531577A5 (https=)
CN111019905A (zh) Car修饰细胞及其在制备自身免疫性疾病药物中的应用
CN110819596B (zh) 具有增强的迁移能力的修饰的细胞
CN112608387B (zh) Cd19和cd20双靶点嵌合抗原受体及其应用
KR20210120019A (ko) 세포-특이적 전사 조절 서열 및 이의 용도
JP2023549780A5 (https=)
JP2023541694A (ja) がん治療剤としての二重特異的抗原結合分子を有するcar発現ナチュラルキラー細胞の生成方法及び組成物
Rhein et al. TCR gene therapy for cancer
AU779462B2 (en) Selectable cell surface marker genes
CN112851826B (zh) Upk2嵌合抗原受体及其尿道癌的治疗